That is exactly what Garnick and company were watching out for in the first look-in. PPHM knows that there have been previous strange anomalies in control arms, and even an outright sabotage of the phase2 trial. So, the tight margin was a smart devise
The tight margin was a smart device? Th ecompany plunged 60% in value. They stopped all bavi/chemo trials. They are getting a delist letter on Monday. They will be booted from Russell funds next month. A RS is nesc. to raise more funds to keep diluting and paying exec monster salaries. Yes, it was such a good device. And Granick is likely gone from pphm at this point. over a month after a futility stop and no word from Chief of Regulatory - not even a quote or excerpt in a pr.